Evan Rachlin
Graduate School Director for the Harvard Medical Alumni Association @ Harvard University
Boston, United States
Evan Rachlin is a Series B investor at Harvard University in Boston focused on Medical and Health Care. Evan Rachlin - Graduate School Director for the Harvard Medical Alumni Association @ Harvard University
- Total investments:
- 10
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Evan Rachlin invests in
Stages Evan Rachlin invests in
Countries Evan Rachlin invests in
Investment Focus
Industry
- Medical 5 (50%)
- Health Care 4 (40%)
- Biotechnology 4 (40%)
- Pharmaceutical 2 (20%)
- Hospital 1 (10%)
Stage
- Series B 4 (40%)
- Series C 2 (20%)
- Funding Round 2 (20%)
- Seed 1 (10%)
- Series A 1 (10%)
Country
- United States 6 (60%)
- Canada 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Triveni Bio
|
Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $65M / Series C / Jun 17, 2026 | |
Iambic
|
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M / Nov 10, 2025 | |
Alpha-9 Oncology
|
Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $175M / Series C / Oct 23, 2024 | |
OrsoBio
|
OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause. | $67M / Series B / Sep 06, 2024 | |
Cardurion Pharmaceuticals
|
Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. | $260M / Series B / Jul 16, 2024 | |
|
Iambic
|
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $100M / Series B / Oct 03, 2023 | |
ADARx Pharmaceuticals
|
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $46M / Series B / Jan 20, 2023 | |
Augmedix
|
Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $17M / Apr 25, 2016 | |
|
Augmedix
|
Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $16M / Series A / Jan 12, 2015 | |
|
Augmedix
|
Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $3.2M / Seed / Jun 16, 2014 |
Co-Investors
About Harvard University
Harvard University is devoted to teaching, learning, and research, and to developing leaders in many disciplines who make a difference globally. Harvard faculty are engaged with teaching and research to push the boundaries of human knowledge. For students who are excited to investigate the biggest issues of the 21st century, Harvard offers anunparalleled student experience and a generous financial aid program, with over $160 million awarded to more than 60% of our undergraduate students. The University has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a truly global education. Harvard University is an ivy league school. Established in 1636, Harvard is the oldest institution of higher education in the United States. The University, which is based in Cambridge and Boston, Massachusetts, has an enrollment of over 20,000-degree candidates, including undergraduate, graduate, and professional students. Harvard has more than 360,000 alumni around the world.
Harvard University Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Angel Morales
Fund Executive Committee
|
|||
Catherine Buell
2024 Harvard Loeb Fellow
|
|||
|
David McCann
Professor
|
|||
David Sinclair
Professor
|
|||
Drew Faust
President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Evan Rachlin invest in?
Evan Rachlin invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Evan Rachlin last invest?
The most recent investment recorded for Evan Rachlin closed in Jun 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
